AlphaFold predicted structure
AGBL1 · Q96MI9

Mean pLDDT
78.3/ 100
Confident
1,112 residues
Confidence breakdown
- Very high(≥ 90)56%
- Confident(70–90)18%
- Low(50–70)5%
- Very low(< 50)21%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
AGBL carboxypeptidase 1
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Corneal abnormalities
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownStructural eye disease
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedFuchs endothelial corneal dystrophy
myasthenia gravis
smoking initiation
cystitis
pneumonia
alcohol drinking
placenta praevia
sign or symptom
dislocation
metabolic disease
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Cytosolic carboxypeptidase 4
Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of tubulin protein. Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate. Also catalyzes the removal of polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK
AGBL1 · Q96MI9

Mean pLDDT
78.3/ 100
Confident
1,112 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0